We are far from reaching the sustainable development goals (SDGs) for health despite a wealth of novel insights in disease mechanisms and possible solutions. Why have we failed in knowledge translation and implementation?
Starting from the case of cardiovascular diseases as one of the most prevalent non-communicable diseases, we examine barriers and hurdles, and perspectives for future health research. Health has multiple links with other SDGs. To accelerate the progress towards a healthy society, health research needs to take a broader view and become more cross-disciplinary and cross-sectoral.
As one example, behavioural studies will underpin better prevention and treatment adherence. The next generation workforce in health and research needs an adapted education and training to implement more effective health approaches.
8-Arm PEG-GA |
|||
abx085109-10kDa1g | Abbexa | 10 kDa; 1 g | EUR 393.6 |
8-Arm PEG-GA |
|||
abx085109-10kDa5g | Abbexa | 10 kDa; 5 g | EUR 744 |
8-Arm PEG-GA |
|||
abx085109-20kDa5g | Abbexa | 20 kDa; 5 g | EUR 744 |
8-Arm PEG-GA |
|||
abx085109-40kDa1g | Abbexa | 40 kDa; 1 g | EUR 427.2 |
4-Arm PEG-GA |
|||
abx085098-100l | Abbexa | 100 µl | EUR 250 |
4-Arm PEG-GA |
|||
abx085098-1ml | Abbexa | 1 ml | Ask for price |
4-Arm PEG-GA |
|||
abx085098-200l | Abbexa | 200 µl | EUR 712.5 |
8-Arm PEG-GA |
|||
abx085109-100l | Abbexa | 100 µl | EUR 250 |
8-Arm PEG-GA |
|||
abx085109-1ml | Abbexa | 1 ml | EUR 275 |
8-Arm PEG-GA |
|||
abx085109-200l | Abbexa | 200 µl | EUR 250 |
4-Arm PEG-GAS |
|||
abx085093-10kDa1g | Abbexa | 10 kDa; 1 g | EUR 526.8 |
4-Arm PEG-GAS |
|||
abx085093-10kDa5g | Abbexa | 10 kDa; 5 g | EUR 878.4 |
4-Arm PEG-GAS |
|||
abx085093-20kDa5g | Abbexa | 20 kDa; 5 g | EUR 878.4 |
4-Arm PEG-GAS |
|||
abx085093-2kDa1g | Abbexa | 2 kDa; 1 g | EUR 477.6 |
4-Arm PEG-GAA |
|||
abx085100-10kDa1g | Abbexa | 10 kDa; 1 g | EUR 460.8 |
4-Arm PEG-GAA |
|||
abx085100-10kDa5g | Abbexa | 10 kDa; 5 g | EUR 760.8 |
4-Arm PEG-GAA |
|||
abx085100-20kDa5g | Abbexa | 20 kDa; 5 g | EUR 760.8 |
4-Arm PEG-GAA |
|||
abx085100-2kDa1g | Abbexa | 2 kDa; 1 g | EUR 427.2 |
8-Arm PEG-GAA |
|||
abx085111-10kDa1g | Abbexa | 10 kDa; 1 g | EUR 393.6 |
8-Arm PEG-GAA |
|||
abx085111-10kDa5g | Abbexa | 10 kDa; 5 g | EUR 744 |
8-Arm PEG-GAA |
|||
abx085111-20kDa5g | Abbexa | 20 kDa; 5 g | EUR 744 |
8-Arm PEG-GAA |
|||
abx085111-40kDa1g | Abbexa | 40 kDa; 1 g | EUR 427.2 |
8-Arm PEG-GAS |
|||
abx085116-10kDa1g | Abbexa | 10 kDa; 1 g | EUR 393.6 |
8-Arm PEG-GAS |
|||
abx085116-10kDa5g | Abbexa | 10 kDa; 5 g | EUR 744 |
8-Arm PEG-GAS |
|||
abx085116-20kDa5g | Abbexa | 20 kDa; 5 g | EUR 744 |
8-Arm PEG-GAS |
|||
abx085116-40kDa1g | Abbexa | 40 kDa; 1 g | EUR 427.2 |
4-Arm PEG-GAS |
|||
abx085093-100l | Abbexa | 100 µl | EUR 312.5 |
4-Arm PEG-GAS |
|||
abx085093-1ml | Abbexa | 1 ml | EUR 350 |
4-Arm PEG-GAS |
|||
abx085093-200l | Abbexa | 200 µl | EUR 312.5 |
4-Arm PEG-GAA |
|||
abx085100-100l | Abbexa | 100 µl | EUR 275 |
4-Arm PEG-GAA |
|||
abx085100-1ml | Abbexa | 1 ml | EUR 300 |
4-Arm PEG-GAA |
|||
abx085100-200l | Abbexa | 200 µl | EUR 275 |
8-Arm PEG-GAA |
|||
abx085111-100l | Abbexa | 100 µl | EUR 250 |
8-Arm PEG-GAA |
|||
abx085111-1ml | Abbexa | 1 ml | EUR 275 |
8-Arm PEG-GAA |
|||
abx085111-200l | Abbexa | 200 µl | EUR 250 |
8-Arm PEG-GAS |
|||
abx085116-100l | Abbexa | 100 µl | EUR 275 |
8-Arm PEG-GAS |
|||
abx085116-1ml | Abbexa | 1 ml | Ask for price |
8-Arm PEG-GAS |
|||
abx085116-200l | Abbexa | 200 µl | EUR 837.5 |
rHu PEG-GCSF (cGMP) |
|||
AK9032-0000 | Akron Biotech | 1mg | Ask for price |
PCL(5K)-PEG-Galactose |
|||
abx085406-2kDa1g | Abbexa | 2 kDa; 1 g | EUR 684 |
PCL(5K)-PEG-Galactose, 2K |
|||
HE116072-2K-G | Biochempeg | G | EUR 430.8 |
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. |
PCL(5K)-PEG-Galactose |
|||
abx085406-100l | Abbexa | 100 µl | EUR 762.5 |
PCL(5K)-PEG-Galactose |
|||
abx085406-1ml | Abbexa | 1 ml | Ask for price |
PCL(5K)-PEG-Galactose |
|||
abx085406-200l | Abbexa | 200 µl | Ask for price |
KRIBIOLISA PEG-GCSF (Pegylated Filgrastim) ELISA |
|||
KBBA10 | Krishgen | 1 x 96 wells | EUR 676.5 |
PEG2-(CH2CO2H)2 |
|||
572081 | MedKoo Biosciences | 1.0g | EUR 260 |
PEG3-(CH2CO2H)2 |
|||
572082 | MedKoo Biosciences | 500.0mg | EUR 610 |
PEG5-(CH2CO2H)2 |
|||
572083 | MedKoo Biosciences | 250.0mg | EUR 530 |
PEG6-(CH2CO2H)2 |
|||
572084 | MedKoo Biosciences | 250.0mg | EUR 530 |
PEG6-(CH2CO2H)2 |
|||
HY-122702 | MedChemExpress | 100mg | EUR 280.8 |
PEG6-(CH2CO2H)2 |
|||
T8232-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: PEG6-(CH2CO2H)2 |
PEG6-(CH2CO2H)2 |
|||
T8232-1g | TargetMol Chemicals | 1g | Ask for price |
Description: PEG6-(CH2CO2H)2 |
PEG6-(CH2CO2H)2 |
|||
T8232-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: PEG6-(CH2CO2H)2 |
PEG6-(CH2CO2H)2 |
|||
T8232-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: PEG6-(CH2CO2H)2 |
PEG6-(CH2CO2H)2 |
|||
T8232-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: PEG6-(CH2CO2H)2 |
AzoDye-2 PEG10 Alkyne |
|||
2435 | AAT Bioquest | 1 mg | EUR 155 |
Description: AzoDye-2 PEG10 alkyne is an excellent building block for labeling azide-containing molecules. |
AzoDye-2 PEG10 Alkyne |
|||
2435-1mg | AAT Bioquest | 1 mg | EUR 151 |
Description: AzoDye-2 PEG10 alkyne is an excellent building block for labeling azide-containing molecules. |
4-Methylumbelliferyl 2-Acetamido-2-deoxy-alpha-D-galactopyranoside PEG2000 Ether |
|||
M333510 | Toronto Research Chemicals | 250mg | EUR 19000 |
(2-pyridyldithio)-PEG4 acid |
|||
T17331-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: (2-pyridyldithio)-PEG4 acid |
(2-pyridyldithio)-PEG4 acid |
|||
T17331-1g | TargetMol Chemicals | 1g | Ask for price |
Description: (2-pyridyldithio)-PEG4 acid |
(2-pyridyldithio)-PEG4 acid |
|||
T17331-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: (2-pyridyldithio)-PEG4 acid |
(2-pyridyldithio)-PEG4 acid |
|||
T17331-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: (2-pyridyldithio)-PEG4 acid |
(2-pyridyldithio)-PEG4 acid |
|||
T17331-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: (2-pyridyldithio)-PEG4 acid |
(2-Pyridyldithio)-PEG2-Boc |
|||
T14018-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: (2-Pyridyldithio)-PEG2-Boc |
(2-Pyridyldithio)-PEG2-Boc |
|||
T14018-1g | TargetMol Chemicals | 1g | Ask for price |
Description: (2-Pyridyldithio)-PEG2-Boc |
(2-Pyridyldithio)-PEG2-Boc |
|||
T14018-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: (2-Pyridyldithio)-PEG2-Boc |
(2-Pyridyldithio)-PEG2-Boc |
|||
T14018-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: (2-Pyridyldithio)-PEG2-Boc |
(2-Pyridyldithio)-PEG2-Boc |
|||
T14018-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: (2-Pyridyldithio)-PEG2-Boc |
JBScreen Classic 2 (PEG 4000 based) |
|||
M-CS-102L | MiTeGen | 24 solutions | EUR 249 |
Description: JBScreen Classic 2 (PEG 4000 based) |
(2-Pyridyldithio)-PEG4-alcohol |
|||
T14019-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: (2-Pyridyldithio)-PEG4-alcohol |
(2-Pyridyldithio)-PEG4-alcohol |
|||
T14019-1g | TargetMol Chemicals | 1g | Ask for price |
Description: (2-Pyridyldithio)-PEG4-alcohol |
(2-Pyridyldithio)-PEG4-alcohol |
|||
T14019-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: (2-Pyridyldithio)-PEG4-alcohol |
(2-Pyridyldithio)-PEG4-alcohol |
|||
T14019-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: (2-Pyridyldithio)-PEG4-alcohol |
(2-Pyridyldithio)-PEG4-alcohol |
|||
T14019-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: (2-Pyridyldithio)-PEG4-alcohol |
pEGFP- MD2- 2 |
|||
PVT10181 | Lifescience Market | 2 ug | EUR 361.2 |
(2-Pyridyldithio)-PEG4-propargyl |
|||
T14020-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: (2-Pyridyldithio)-PEG4-propargyl |
(2-Pyridyldithio)-PEG4-propargyl |
|||
T14020-1g | TargetMol Chemicals | 1g | Ask for price |
Description: (2-Pyridyldithio)-PEG4-propargyl |
(2-Pyridyldithio)-PEG4-propargyl |
|||
T14020-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: (2-Pyridyldithio)-PEG4-propargyl |
(2-Pyridyldithio)-PEG4-propargyl |
|||
T14020-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: (2-Pyridyldithio)-PEG4-propargyl |
(2-Pyridyldithio)-PEG4-propargyl |
|||
T14020-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: (2-Pyridyldithio)-PEG4-propargyl |
(2-pyridyldithio)-PEG1-hydrazine |
|||
T38503-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: (2-pyridyldithio)-PEG1-hydrazine |
(2-pyridyldithio)-PEG1-hydrazine |
|||
T38503-1g | TargetMol Chemicals | 1g | Ask for price |
Description: (2-pyridyldithio)-PEG1-hydrazine |
(2-pyridyldithio)-PEG1-hydrazine |
|||
T38503-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: (2-pyridyldithio)-PEG1-hydrazine |
(2-pyridyldithio)-PEG1-hydrazine |
|||
T38503-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: (2-pyridyldithio)-PEG1-hydrazine |
(2-pyridyldithio)-PEG1-hydrazine |
|||
T38503-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: (2-pyridyldithio)-PEG1-hydrazine |
pEGFP-C1-2 |
|||
PVT14810 | Lifescience Market | 2 ug | EUR 444 |
JBScreen Membrane 2 (PEG 2000 MME to PEG 10000 based) |
|||
M-CS-302L | MiTeGen | 24 solutions | EUR 414 |
Description: JBScreen Membrane 2 (PEG 2000 MME to PEG 10000 based) |
PEG-2 Hydrogenated Tallow Amine |
|||
P159960 | Toronto Research Chemicals | 1g | EUR 673 |
Description: 61791-26-2 |
pEGFP-TGFB1-2 |
|||
PVT17860 | Lifescience Market | 2 ug | EUR 309.6 |
DBCO-(PEG2-Val-Cit-PAB)2 |
|||
T17788-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: DBCO-(PEG2-Val-Cit-PAB)2 |
DBCO-(PEG2-Val-Cit-PAB)2 |
|||
T17788-1g | TargetMol Chemicals | 1g | Ask for price |
Description: DBCO-(PEG2-Val-Cit-PAB)2 |
DBCO-(PEG2-Val-Cit-PAB)2 |
|||
T17788-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: DBCO-(PEG2-Val-Cit-PAB)2 |
DBCO-(PEG2-Val-Cit-PAB)2 |
|||
T17788-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: DBCO-(PEG2-Val-Cit-PAB)2 |
DBCO-(PEG2-Val-Cit-PAB)2 |
|||
T17788-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: DBCO-(PEG2-Val-Cit-PAB)2 |
DBCO-(PEG2-VC-PAB-MMAE)2 |
|||
T17789-10mg | TargetMol Chemicals | 10mg | Ask for price |
Description: DBCO-(PEG2-VC-PAB-MMAE)2 |
DBCO-(PEG2-VC-PAB-MMAE)2 |
|||
T17789-1g | TargetMol Chemicals | 1g | Ask for price |
Description: DBCO-(PEG2-VC-PAB-MMAE)2 |
DBCO-(PEG2-VC-PAB-MMAE)2 |
|||
T17789-1mg | TargetMol Chemicals | 1mg | Ask for price |
Description: DBCO-(PEG2-VC-PAB-MMAE)2 |
DBCO-(PEG2-VC-PAB-MMAE)2 |
|||
T17789-50mg | TargetMol Chemicals | 50mg | Ask for price |
Description: DBCO-(PEG2-VC-PAB-MMAE)2 |
DBCO-(PEG2-VC-PAB-MMAE)2 |
|||
T17789-5mg | TargetMol Chemicals | 5mg | Ask for price |
Description: DBCO-(PEG2-VC-PAB-MMAE)2 |
Peg12 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
K6370803 | ABM | 1.0 ug DNA | EUR 184.8 |
PEG10 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
K1626703 | ABM | 1.0 ug DNA | EUR 184.8 |
Peg12 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
K3769503 | ABM | 1.0 ug DNA | EUR 184.8 |
Peg10 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
K4676403 | ABM | 1.0 ug DNA | EUR 184.8 |
PEG10 (untagged)-Human paternally expressed 10 (PEG10) transcript variant 2 |
|||
SC328643 | Origene Technologies GmbH | 10 µg | Ask for price |
JBScreen PEG/Salt 2 |
|||
CS-142 | Jena Bioscience GmbH | 24solutions | EUR 229.9 |
JBScreen PEG/Salt 2 |
|||
M-CS-142 | MiTeGen | 24 solutions | EUR 263 |
Description: JBScreen PEG/Salt 2 |
Absolute Mag™ PEG300 Magnetic Polystyrene Particles, 2 μm |
|||
WHM-G393 | Creative Diagnostics | 10 ml | EUR 1160 |
PEG10 (GFP-tagged) - Human paternally expressed 10 (PEG10), transcript variant 2 |
|||
RG231502 | Origene Technologies GmbH | 10 µg | Ask for price |
PEG10 (GFP-tagged) - Human paternally expressed 10 (PEG10), transcript variant 2 |
|||
RG230005 | Origene Technologies GmbH | 10 µg | Ask for price |
PEG10 (Myc-DDK-tagged)-Human paternally expressed 10 (PEG10), transcript variant 2 |
|||
RC231502 | Origene Technologies GmbH | 10 µg | Ask for price |
As well, only effective dialogue and communication between researchers, practitioners, society and policymakers can lead to translation of evidence into policies, addressing the complexity of socioeconomic factors and commercial interests. Within Europe, health research needs a comprehensive vision and strategy that connects to achieving better health, as one of the interconnected SDGs.